FAQ

mondoBIOTECH holding AG (“hereinafter alternatively referred to as “mondoBIOTECH”, “We” or the “Company”, and together with its subsidiaries, the “Group”) focuses on bioinformatics’ analysis of immunomodulating substances that are naturally occurring in the human body in order to identify promising candidates for the development of medicinal products specifically targeted to the treatment of rare and neglected diseases. It is the intention of the Company to license or sell such medicinal product candidates to third parties in order to advance their late-stage development and to authorize their marketing and distribution.

Please feel free to download our pipeline at the following link Product pipeline

We advance our medicinal product candidates portfolio by (i) bringing our pipeline to the awareness of the mondoBIOTECH Community, (ii) interacting and networking with the mondoBIOTECH Community in order to explore more innovative ways to develop, finance, promote and commercialize our medicinal product candidates and (iii) licensing or selling our medicinal product candidates to third parties after having protected our product with patent applications and/or orphan drug designations.

Our biggest challenge is to be able to find therapeutic solutions for as many of the 7,000 rare diseases as possible. This implies the capability to increase the awareness of the problem of rare diseases in the mondoBIOTECH Community because only with the power of collaboration with the continuously expanding mondoBIOTECH Community for rare diseases can we achieve concrete and meaningful results.

We operate with a continuously expanding community (scientists, physicians, patients, patient advocacy organizations etc.) who share its experience, know-how, expertise and skills with us and like us is dedicated to the search of treatments for rare and neglected diseases.

Dry search rather than classical laboratory research (Search & Match): We search using IT tools and methods the vast amount of globally available data on biological and medical activities with known peptides and other biological immunomodulating substances rather than by engaging in the traditional approach of drug discovery.

Focus on bioactive substances of human origin:
Peptides of human origin often offer better efficacy and safety profiles compared to many other classes of molecular entities.

Focus on rare and neglected diseases:
Rare and neglected diseases offer strong competitive advantages and drugs for those diseases the long awaited relief for many affected patients.

Protection of the business:
Innovative intellectual property concepts and market protection through Orphan Medicinal Product Designations (OMPD) giving regulatory exclusivity for as much as seven years in the US, and 10 years in Europe and some other parts of the world.

Mondobiotech uses existing medical literature to match peptide therapies to diseases that might be efficacious in treating. The intellectual property developed by the company is licensed to other companies for further development.

Mondobiotech receives sign-up fees, milestones and royalties from its many licensed products. In relationship to certain licensing agreements partners may request additional development services that Mondobiotech provides.

The company’s growth is driven by the continuous development of its pipeline. This means both advancing through the stages of the development process and/or increasing the number licensing agreements.

Our customers are entities with an interest in having new medicinal products for the treatment of rare and neglected diseases available on the market.

Mondobiotech is currently partnered with Lung Rx (a wholly-owned subsidiary of United Therapeutics), Intermune, Biogen, the peptide manufacturer Bachem and the genetic testing company 23andMe.

Medicinal product candidates are natural peptide of human origin with known biologic activity that we redirect for the treatment of rare and neglected diseases. Download a copy of the Product pipeline

Any entity with an interest in having and/or the capacity to bring a medicinal product for the treatment of rare and neglected diseases on/to the market.

The headquarters of Mondobiotech is located in Stans; the company has subsidiaries across Switzerland, in Germany, Liechtenstein and the United States.

Mondobiotech networks with physicians and researchers who specialize in specific rare diseases, and with patients who suffer from a rare disease.

The company has approximately 25 employees.

Aviptadil has been licensed for development and marketing to Lung Rx, a wholly-owned subsidiary of United Therapeutics Corporation. For more information please contact science@mondobiotech.com.

A disease or disorder is “rare” if only a limited percentage of the general population is affected by it. In the US a “rare” disease is one affecting fewer than 200,000 Americans, and in Europe a “rare” disease is one affecting less than 5 in 10,000 people.

There are approximately 7,000 known rare and neglected diseases.

Not many pharmaceutical companies focus on developing treatments for rare diseases, largely because they can be costly to develop and do not always yield significant financial returns. Governments in the US and Europe offer some incentives to companies who do research these diseases, giving their product candidates the “orphan drug status” designation, which Mondobiotech has received for several of its products.

Peptides are the building blocks of proteins; polymers (molecular structures connected by covalent chemical bonds) linked in a specific order with amino acids.

Peptides are well-known and frequently referenced in medical literature. They are produced in the human body, and usually have obvious efficacies and well-described safety profiles, which means they are unlikely to cause unexpected side-effects in treatment.

Mondobiotech was founded after researchers decoded the Human Genome in 2001. Fueled by the idea that 80% of rare diseases were genetic, the founders wanted to develop an innovative company to focus on an area neglected by mainstream pharmaceutical companies.

Investor & External Relations Department Contacts:
Maria Teresa D'Antonangelo Bühlmann
mondoBIOTECH holding AG
Mürgstrasse 18
CH-6370 Stans
Switzerland
T. +41 (0)840 200 010
F. +41 (0)840 200 011
investor@mondobiotech.com

Any entity with an interest in having and/or the capacity to bring a medicinal product for the treatment of rare and neglected diseases on/to the market.

These documents are available to download here.

The headquarters of Mondobiotech is located in Stans; the company has subsidiaries across Switzerland, in Germany, Liechtenstein and the United States.

PricewaterhouseCoopers AG, Basel.

The company has approximately 25 employees.

Please refer to your deposit custody bank.

26th of August 2009 with the symbol RARE at the SIX Swiss Exchange.

With Hambrecht Mondobiotech expects to raise the funds to finance the further development of the pipeline, which will maximize the growth of the company.

On 1 February 2010, the Group finalized a strategic partnership with LungRX LLC, a wholly-owned subsidiary of United Therapeutics, Inc. (Nasdaq: UTHR), focused on the development of Aviptadil in pulmonary arterial hypertension (PAH), Sarcoidosis, idiopathic pulmonary fibrosis (IPF) and acute respiratory distress syndrome (ARDS). United Therapeutics will be responsible for further development and commercialization of the Aviptadil platform. The new agreement with United Therapeutics represents a continuation of the prior agreement with Biogen Idec MA, Inc., which remains in the development project with financial interests with respect to the treatment of PAH with Aviptadil only.

1.436 million common shares.

The website is the principal instrument of communication between the company and the public, and is the networking and communication tool between the company and the community.

mondoBIOTECH holding AG ("hereinafter alternatively referred to as "mondoBIOTECH", "We" or the "Company", and together with its subsidiaries, the "Group") focuses on bioinformatics' analysis of immunomodulating substances that are naturally occurring in the human body in order to identify promising candidates for the development of medicinal products specifically targeted to the treatment of rare and neglected diseases. It is the intention of the Company to license or sell such medicinal product candidates to third parties in order to advance their late-stage development and to authorize their marketing and distribution.

We advance our medicinal product candidates portfolio by (i) bringing our pipeline to the awareness of the mondoBIOTECH Community, (ii) interacting and networking with the mondoBIOTECH Community in order to explore more innovative ways to develop, finance, promote and commercialize our medicinal product candidates and (iii) licensing or selling our medicinal product candidates to third parties after having protected our product with patent applications and/or orphan drug designations.

SIX Swiss Exchange AG, RARE. You can have more information on Mondobiotech shares in the section “Stock information” www.six-swiss-exchange.com

You will find all Mondobiotech news on the SIX german webpage. You can regularly receive Mondobiotech’s new by subscribing to our newsletter service in the Stay Informed section of Mondobiotech website.

See How to invest section for more information

Our biggest challenge is to be able to find therapeutic solutions for as many of the 7,000 rare diseases as possible. This implies the capability to increase the awareness of the problem of rare diseases in the mondoBIOTECH Community because only with the power of collaboration with the continuously expanding mondoBIOTECH Community for rare diseases can we achieve concrete and meaningful results.

You can buy Shares form the Company in its different offerings. See How to invest section for more information.

In the classical pharmaceutical and biotech field there is no correlation between resources invested in R&D and the resulting output obtained, at least not measurable in the numbers of new medicaments. Therefore, other value drivers probably characterize the development process. In-depth information exchange, interaction, versatility and flexibility are such value drivers.

We operate with a continuously expanding community (scientists, physicians, patients, patient advocacy organizations etc.) who share its experience, know-how, expertise and skills with us and like us is dedicated to the search of treatments for rare and neglected diseases.

Dry search rather than classical laboratory research (Search & Match): We search using IT tools and methods the vast amount of globally available data on biological and medical activities with known peptides and other biological immunomodulating substances rather than by engaging in the traditional approach of drug discovery.

Focus on bioactive substances of human origin:
Peptides of human origin often offer better efficacy and safety profiles compared to many other classes of molecular entities.

Focus on rare and neglected diseases:
Rare and neglected diseases offer strong competitive advantages and drugs for those diseases the long awaited relief for many affected patients.

Protection of the business:
Innovative intellectual property concepts and market protection through Orphan Medicinal Product Designations (OMPD) giving regulatory exclusivity for as much as seven years in the US, and 10 years in Europe and some other parts of the world.

Not yet.

Mondobiotech uses existing medical literature to match peptide therapies to diseases that might be efficacious in treating. The intellectual property developed by the company is licensed to other companies for further development.

We disclose on a half-yearly basis. See our Corporate Events in Appointments

Mondobiotech receives sign-up fees, milestones and royalties from its many licensed products. In relationship to certain licensing agreements partners may request additional development services that Mondobiotech provides.

Usually the annual Shareholders meeting is held at the headquarters in Stans during the month of April.

The company’s growth is driven by the continuous development of its pipeline. This means both advancing through the stages of the development process and/or increasing the number licensing agreements.

The 31st of December.

Our customers are entities with an interest in having new medicinal products for the treatment of rare and neglected diseases available on the market.

You will receive an invitation to attend the Shareholder’s Meeting only if you are registered into the shareholder’s Register.
The address of the Shareholder’s Register is:
Mondobiotech holding AG
c/o SIX SAG AG
Baslerstrasse 90
P.O. Box
CH- 4601 Olten, Switzerland

Mondobiotech is currently partnered with Lung Rx (a wholly-owned subsidiary of United Therapeutics), Intermune, Biogen, the peptide manufacturer Bachem and the genetic testing company 23andMe.

To register please contact your deposit custody bank. Only your deposit custody bank can apply for registration to the Shareholders register.

Medicinal product candidates are natural peptide of human origin with known biologic activity that we redirect for the treatment of rare and neglected diseases. Download a copy of the Product pipeline

Annual reports, financial disclosures, etc. can be downloaded here.

1.436 million common shares and 52.901 million voting right shares.